TCM
RNAC icon

Tang Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Tang Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,333
Closed -$276K – 123
2023
Q4 		$276K Hold
13,333
– – 0.03% 121
2023
Q3 		$424K Hold
13,333
– – 0.06% 98
2023
Q2 		$448K Buy
+13,333
New +$477K 0.07% 89

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tang Capital Management's RNAC Position: Q1 2024 in Review

Tang Capital Management sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 13,333 shares — an estimated $276K sold.

Tang Capital Management first reported a position in RNAC in Q2 2023 and held it in 3 quarters. The position peaked at $448K in Q2 2023. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Tang Capital Management reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 13,333 Cartesian Therapeutics shares in Q1 2024, an estimated $276K.
  • Tang Capital Management first reported a position in Cartesian Therapeutics in Q2 2023 and held it in 3 quarters.
  • Tang Capital Management's Cartesian Therapeutics position peaked at $448K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.